Independent Ireland TD Ken O’Flynn has called for urgent answers from Government after the HSE confirmed that more than €52 million has been spent funding gender-related psychological services abroad for minors since 2020 under the Treatment Abroad Scheme.
Figures released to Deputy O’Flynn show that 1,257 overseas episodes of care were funded for under-18s between 2020 and 2025. The figures also show approvals rising from 177 cases in 2020 to 246 in 2025, with annual expenditure exceeding €11.4 million in 2025 alone.
Deputy O’Flynn said the disclosures raise serious questions around governance, accountability and oversight.
“The HSE cannot simultaneously claim there is no comprehensive national data system while producing detailed approval numbers, expenditure figures and treatment activity under this scheme,” he said.
“That contradiction goes to the core of public accountability.”
Deputy O’Flynn said the issue extends beyond ideology and raises significant questions regarding safeguarding, oversight and financial governance.
“We are dealing with minors,” he said.
“The State has now confirmed tens of millions of euro in overseas treatment expenditure involving children and adolescents, yet there appears to be no transparent national audit structure, no published long-term outcomes framework, and no clearly defined independent oversight mechanism.
“That is extraordinary.”
The HSE also confirmed that no under-18 surgical procedures were funded abroad under the scheme during the years outlined. However, Deputy O’Flynn said this does not remove the need for scrutiny of the broader treatment pathway.
“No serious Government should permit this scale of expenditure and cross-border clinical referral activity without robust governance, independent review and full transparency,” he said.
Deputy O’Flynn confirmed that he has lodged further Parliamentary Questions seeking details on the clinics and jurisdictions involved, safeguarding arrangements for minors referred abroad, audit and value-for-money reviews, long-term outcome monitoring, the legal and clinical basis underpinning approvals, and total associated travel and ancillary costs.
“The public deserves facts, transparency and accountability,” he said.
“Instead, what we are seeing is fragmentation, opacity and institutional defensiveness.
“This issue is far too serious for vague answers and bureaucratic evasions.”


